Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer's disease (from the Nakayama Study).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 09 2022
08 09 2022
Historique:
received:
11
03
2022
accepted:
01
09
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
Alzheimer's disease (AD) is a progressive disease, and the number of AD patients is increasing every year as the population ages. One of the pathophysiological mechanisms of AD is thought to be the effect of metabolomic abnormalities. There have been several studies of metabolomic abnormalities of AD, and new biomarkers are being investigated. Metabolomic studies have been attracting attention, and the aim of this study was to identify metabolomic biomarkers associated with AD and mild cognitive impairment (MCI). Of the 927 participants in the Nakayama Study conducted in Iyo City, Ehime Prefecture, 106 were selected for this study as Control (n = 40), MCI (n = 26), and AD (n = 40) groups, matched by age and sex. Metabolomic comparisons were made across the three groups. Then, correlations between metabolites and clinical symptoms were examined. The blood mRNA levels of the ornithine metabolic enzymes were also measured. Of the plasma metabolites, significant differences were found in ornithine, uracil, and lysine. Ornithine was significantly decreased in the AD group compared to the Control and MCI groups (Control vs. AD: 97.2 vs. 77.4; P = 0.01, MCI vs. AD: 92.5 vs. 77.4; P = 0.02). Uracil and lysine were also significantly decreased in the AD group compared to the Control group (uracil, Control vs. AD: 272 vs. 235; P = 0.04, lysine, Control vs. AD: 208 vs. 176; P = 0.03). In the total sample, the MMSE score was significantly correlated with lysine, ornithine, thymine, and uracil. The Barthel index score was significantly correlated with lysine. The instrumental activities of daily living (IADL) score were significantly correlated with lysine, betaine, creatine, and thymine. In the ornithine metabolism pathway, the spermine synthase mRNA level was significantly decreased in AD. Ornithine was decreased, and mRNA expressions related to its metabolism were changed in the AD group compared to the Control and MCI groups, suggesting an association between abnormal ornithine metabolism and AD. Increased betaine and decreased methionine may also have the potential to serve as markers of higher IADL in elderly persons. Plasma metabolites may be useful for predicting the progression of AD.
Identifiants
pubmed: 36075959
doi: 10.1038/s41598-022-19670-y
pii: 10.1038/s41598-022-19670-y
pmc: PMC9458733
doi:
Substances chimiques
Biomarkers
0
RNA, Messenger
0
Betaine
3SCV180C9W
Ornithine
E524N2IXA3
Lysine
K3Z4F929H6
Thymine
QR26YLT7LT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15205Informations de copyright
© 2022. The Author(s).
Références
Environ Health Prev Med. 2020 Oct 31;25(1):64
pubmed: 33129280
BBA Clin. 2016 Apr 03;5:151-8
pubmed: 27114925
Mol Neurobiol. 2020 Dec;57(12):4941-4951
pubmed: 32816243
J Alzheimers Dis. 2020;74(1):277-286
pubmed: 32007958
PLoS One. 2013 Sep 18;8(9):e73814
pubmed: 24058493
PLoS One. 2015 Mar 24;10(3):e0119452
pubmed: 25803028
BMC Genomics. 2021 Apr 20;22(1):287
pubmed: 33879046
Alzheimers Dement. 2018 Jun;14(6):707-722
pubmed: 29316447
J Clin Lab Anal. 2017 Sep;31(5):
pubmed: 28671332
J Alzheimers Dis. 2021;79(2):639-652
pubmed: 33337369
Front Immunol. 2021 Jan 14;11:582998
pubmed: 33519806
Hum Psychopharmacol. 2014 Mar;29(2):190-8
pubmed: 24590544
Lancet Neurol. 2022 Jan;21(1):66-77
pubmed: 34838239
J Inherit Metab Dis. 2011 Feb;34(1):3-15
pubmed: 20446114
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209
pubmed: 32690803
J Alzheimers Dis. 2020;78(4):1381-1392
pubmed: 33164929
Sci Rep. 2019 Sep 24;9(1):13764
pubmed: 31551443
Bioanalysis. 2018 Sep 1;10(18):1525-1546
pubmed: 30198770
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 1;1091:53-66
pubmed: 29852382
J Alzheimers Dis. 2021;84(1):23-50
pubmed: 34511504
Sci Rep. 2017 Jul 7;7(1):4855
pubmed: 28687801
Metabolomics. 2021 Aug 28;17(9):78
pubmed: 34453619
Transl Psychiatry. 2014 Apr 08;4:e379
pubmed: 24713860
J Psychiatr Res. 2015 Jul-Aug;66-67:1-6
pubmed: 25943949
Front Pharmacol. 2021 Jul 21;12:700587
pubmed: 34366852
Anal Chem. 2009 Aug 1;81(15):6165-74
pubmed: 19522513
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Proteome Res. 2003 Sep-Oct;2(5):488-94
pubmed: 14582645